US Morning Headlines: Congress threatens fresh Iran sanctions, Banks consi...

To view this email as a webpage, click here     Monday November 11 2013     US homepage   Congress threatens fresh Iran sanctions   Kerry on defensive after criticism, while Iran blames France for blocking a historic agreement and Israel denounces US strategy on Tehran       Banks consider chat room ban for traders     Democrats want US tax breaks slashed     ECB split stokes German backlash fears     BP in fresh attempt to curb spill payouts         Video   ANZ sees further growth in mining   Mike Smith, chief executive of ANZ, talks to the FT's Jeremy Grant about the Australian economy and the banks expansion plans in Asia. Far from coming to the end of the commodities boom, Mr Smith new projects should provide new impetus to the sector, but that the wider Australian economy needs modernisation.   Markets   European stocks firm on economic optimism   Bourses mostly higher, albeit modestly, as traders digest a positive US jobs report and Chinese data showing consumer price inflation for October was lower than expected       Follow Buffett and back pricing power     ECB must prevent euro aping strong yen     Local currency bond market given revamp     Lonmin climbs on flat European indices   World News   France says Iran deal is 'not far'   France's foreign minister says 'We are not far from an accord', rejecting claims that his country scuppered an agreement over Iran's nuclear programme       Poland struggles to break coal dependency     Bloomberg quashes report to stay in China     Argentina's Fernández picks new battle     Security fears over Lebanese Shia parades   US news   Kerry looks for allies at home and abroad   Breakdown in talks and public criticism from France has exposed US administration to pressure in Congress as well as from friends in the Middle East       Canada's housing market teeters precariously     France blamed for blocking Iran deal     World diary: November 11 – November 17   US & Canadian companies   Shire buys ViroPharma for $4.2bn   London-listed pharmaceuticals group says the deal will boost its rare disease unit and generate cost synergies of about $150m by 2015       Culture clash key to Cooper Tire impasse     KPMG treads new ground with fund     Investor campaigns double in three years     IAC: All the single companies         Manage email    Forward this email   Feedback    Manage portfolio Subscribe to the FT Follow the FT   Unsubscribe | My Account | RSS | Privacy Policy | About Us | Help   © THE FINANCIAL TIMES LTD 2013 You have received this email because you have signed up from the NBE preference page. This email was sent by a company owned by Pearson plc, registered office at 80 Strand, London WC2R 0RL. Registered in England and Wales with company number 53723.